Less than a month after the U.S. Food and Dr-g Administration (FDA) gave its antidepressant dr-g zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its dr-g development efforts and laying off 40% of its workforce.
https://www.outsourcing-pharma.com/Article/2023/09/04/layoffs-as-sage-therapeutics-reshuffles-cns-pipeline